Table of Contents
A contract development and manufacturing organisation’s (CDMO’s) stated capacity for pre-filled syringe production is not the same as its verified, available and scalable capacity. For development and operations leaders making long-term sourcing decisions, understanding this distinction is essential. The metrics that matter are: declared annual unit output against demonstrated line utilisation, filling line speed and technology configuration, automated inspection throughput, packaging line flexibility, lead time transparency and scale-up readiness supported by a structured technology transfer process.
This article sets out each of those metrics in detail and identifies the specific evidence buyers should request before committing to a CDMO partner for large-scale commercial pre-filled syringe manufacturing.
Why Capacity Assessment Requires Structured Due Diligence
Pre-filled syringe production sits at the intersection of several operational risks: aseptic process complexity, high-speed automation, container-closure integrity requirements and multi-authority regulatory oversight. A CDMO that can fill 100,000 syringes for a clinical campaign does not automatically have the scheduling headroom, the validated process range or the regulatory standing to supply 150 million units annually to global markets.
Buyers who rely solely on brochure figures when selecting a partner expose their supply chain to risks including unplanned downtime, capacity conflicts with incumbent customers, failed line clearances and delays at the inspection and packaging stage. Structured capacity due diligence reduces these risks before any agreement is signed.
The Primary Metrics That Define Pre-Filled Syringe Capacity
Declared Annual Output Versus Available Capacity
A CDMO’s headline annual output figure reflects the theoretical maximum if all lines operate at full speed with no downtime, no cleaning cycles and no changeovers. Buyers should request the facility’s net available capacity: the annual unit figure after scheduled maintenance, cleaning validation cycles, format changeovers, quality holds and existing customer commitments are accounted for.
The question to ask is not “what is your total capacity?” but “what capacity can you commit to my programme, and on what scheduling basis?”
Line Speed and Throughput Benchmarks
Line speed for pre-filled syringe filling is measured in units per minute and should be verified against the specific format you require. A CDMO operating at 540 syringes per minute on a 1 mL format may achieve a different net throughput on a 0.5 mL format depending on equipment configuration.
Request the validated fill speed for your specific container format and product viscosity class. Line speed figures that are not tied to a validated process parameter are not meaningful for capacity planning.
Number of Filling Lines and Technology Configuration
Redundancy is a core capacity signal. A facility operating a single filling line has no fallback if that line requires unplanned maintenance. Two or more filling lines, each equipped with Restricted Access Barrier Systems (RABS), provide a more resilient supply basis and greater scheduling flexibility.
RABS technology is the current Good Manufacturing Practice (GMP) standard for commercial aseptic pre-filled syringe production, providing a physical separation between the operator and the critical filling zone without the full enclosure of an isolator. Buyers should confirm both the number of lines and the barrier technology protecting each one.
Container Format Range
Commercial pre-filled syringe supply often involves more than one container configuration. A CDMO that can accommodate standard syringe formats alongside specialised or plastic-free formats provides operational flexibility if your product line evolves. Verify which formats are validated and which remain in development.
Automated Inspection Throughput
Visual inspection is a mandatory step before release of any sterile injectable product and is frequently the throughput bottleneck in high-volume production. A 100% automated inspection system operating at a higher speed than the filling line ensures that inspection does not constrain overall output.
Request the validated inspection speed, the detection technologies deployed (particulate detection, cosmetic inspection and container closure integrity) and whether the inspection system is fully integrated with the filling line or operates as a separate downstream step.
Packaging Line Capacity and Format Flexibility
Packaging capacity is rarely discussed with the same rigour as filling capacity in early CDMO conversations, yet it directly determines the speed at which finished product enters the supply chain. Buyers should assess the number of packaging lines, their throughput speed, the range of kit formats supported and whether dedicated lines exist for specialist packaging requirements.
For products entering regulated markets with specific serialisation or traceability requirements, confirm that the packaging operation is compliant with the relevant track-and-trace regulations.
Evaluating Lead Times and Scheduling Transparency
Lead time in pre-filled syringe production covers two distinct periods: the time from contract signature to first GMP batch (which includes technology transfer, process development and equipment validation) and the ongoing campaign lead time for each production run within an established programme.
Buyers should request both figures. A CDMO may be able to execute a validated campaign rapidly once the process is established, but if the technology transfer phase requires significant time, this must be factored into launch planning. When evaluating a CDMO, ask specifically about the following:
- What is the typical duration from feasibility assessment to first GMP batch for a comparable product type?
- What is the minimum notice period required for a scheduled production campaign?
- How are urgent or accelerated campaigns accommodated, and at what cost?
- How is scheduling communicated and what visibility does the customer have into the production calendar?
Assessing Scale-Up and Technology Transfer Readiness
Scale-up readiness is the ability of a CDMO to translate a clinical or early-commercial process into a validated, reproducible large-scale operation without introducing new sources of variability. For pre-filled syringe production, this encompasses formulation compatibility with high-speed filling equipment, container-closure interaction studies, sterilisation validation and aseptic process simulation (also known as media fill validation).
The technology transfer process should be documented, milestone-driven and managed by a dedicated project team. When reviewing a CDMO’s scale-up capability, request the following:
- A standard technology transfer protocol or template
- A list of comparable technology transfers completed in the last three years, including product type and scale
- Evidence of process performance qualification data for the relevant filling line
- Documented Aseptic Process Simulation (APS) results for the line to be used
A CDMO that cannot provide this level of documentation is not demonstrating scale-up readiness; it is asking the buyer to accept that readiness on faith.
Regulatory Certification as a Capacity Signal
Regulatory certification is not only a compliance requirement; it is a practical indicator of a facility’s operational discipline and its ability to supply product to specific markets. A site certified by multiple international health authorities has demonstrated that its documentation, processes and quality systems can withstand repeated, rigorous inspection.
For buyers supplying the United States and European markets simultaneously, a facility holding both EU Good Manufacturing Practice (EU-GMP) certification and United States Food and Drug Administration (US FDA) certification removes the need for duplicate manufacturing sites and simplifies the overall supply chain.
For buyers targeting the Japanese market, the pathway is more complex. Japan’s Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) apply distinct inspection standards, and access to the Japanese market typically requires either a local Marketing Authorisation Holder or a Designated Marketing Authorisation Holder arrangement. A CDMO with an established presence in Japan or with validated relationships to facilitate Japanese market entry adds meaningful strategic value here.
The Evidence Buyers Should Request Before a Decision
The following list consolidates the specific evidence that development and operations leaders should request during CDMO evaluation for commercial pre-filled syringe production:
- Net available capacity figures: Annual unit output after accounting for all scheduled downtime, changeovers and existing customer commitments
- Validated line speed data: For the specific container format and fill volume relevant to your product
- RABS or barrier technology documentation: Confirming the aseptic environment classification and validation status of each filling line
- Automated inspection performance data: Speed, detection technology and integration status
- Packaging line specifications: Throughput, kit format range and serialisation compliance
- Technology transfer protocol and case studies: With comparable product types and scale
- Aseptic Process Simulation records: For the specific filling line proposed for your programme
- Regulatory inspection history: Including the most recent GMP inspection report summary and any outstanding observations
- Certification portfolio: Confirming which international health authorities have inspected and approved the site
- Lead time commitments in writing: Covering both technology transfer timelines and ongoing campaign scheduling
Adragos Pharma’s Commercial Pre-Filled Syringe Capabilities
Adragos Pharma operates a large-scale commercial pre-filled syringe manufacturing facility at Maisons-Alfort, France, within its sterile manufacturing cluster. The site provides a reference point for how the metrics described above can be evaluated in practice.
The Maisons-Alfort facility operates two filling lines, each equipped with Restricted Access Barrier Systems (RABS), with a maximum filling capacity of up to 540 syringes per minute. Annual production capacity reaches 150 million units. Container formats supported include 0.5 mL and 1 mL, across three pre-filled syringe configurations: Standard, Preventis™ and Eris™.
Automated inspection is performed by two Seidenader systems operating at up to 600 units per minute, delivering 100% automated visual inspection at a throughput rate that exceeds filling speed. The facility operates five packaging lines, all thermoforming-based, including a dedicated plastic-free packaging line for the Eris™ syringe format. Packaging speeds reach up to 360 syringes per minute, with kit configurations ranging from 2-syringe to 76-syringe packs, including Bag-in-Bag options.
The site holds EU-GMP certification and is engineered for United States Food and Drug Administration readiness, and has been certified by 12 international health authorities, supporting global commercial supply across multiple regulated markets.
For buyers requiring clinical-stage development and smaller-batch fill-finish prior to commercial scale-up, Adragos also operates a dedicated aseptic fill-finish facility in Jura, Switzerland, supporting liquid and lyophilised vials with no minimum batch size and a three-month turnaround from order to batch. This allows a consistent technology and quality framework from clinical development through to high-volume commercial supply, managed across a single CDMO relationship.
Further information on Adragos Pharma’s sterile manufacturing network is available at www.adragos-pharma.com.
Questions to Ask Before Signing a Manufacturing Agreement
The following questions consolidate the due diligence framework into a practical checklist for sourcing conversations with prospective CDMO partners:
- What is your net committed capacity for our volume, and how is it protected contractually?
- Which filling lines would be assigned to our programme, and what is their current utilisation rate?
- What is the validated fill speed for our specific container format?
- How many completed technology transfers of comparable complexity can you reference?
- What does your Aseptic Process Simulation programme cover, and how recently were the relevant lines qualified?
- Which regulatory authorities have inspected this facility, and what is the outcome of the most recent inspection?
- How do you manage scheduling conflicts between customers during peak demand?
- What is your minimum lead time for a scheduled production campaign once the process is established?
FAQs About CDMO Capacity for Pre-Filled Syringes
What metrics define a CDMO’s capacity for pre-filled syringe production?
The primary metrics are net available annual unit output (after accounting for downtime, changeovers and existing customer commitments), validated filling line speed for the specific container format, the number of filling lines and the barrier technology protecting each one, automated inspection throughput and detection capability, and packaging line speed and format flexibility. Technology transfer track record and regulatory certification breadth are also key indicators of operational readiness for commercial supply.
What is the difference between declared capacity and available capacity at a CDMO?
Declared capacity is the theoretical maximum output a filling line can achieve when operating continuously at full speed. Available capacity is the net output remaining after scheduled maintenance, cleaning validation cycles, format changeovers, quality holds and commitments already in place for other customers are deducted. The difference between these two figures is frequently significant. Buyers should always request net committed capacity, not headline production statistics, when evaluating a CDMO for commercial pre-filled syringe supply.
What is Restricted Access Barrier Systems (RABS) technology in aseptic filling?
Restricted Access Barrier Systems (RABS) technology provides a physical barrier between the operator and the critical filling zone in an aseptic manufacturing environment, reducing the risk of microbial contamination without the full enclosure of an isolator. RABS is the current Good Manufacturing Practice (GMP) standard for commercial aseptic pre-filled syringe production. It enables high-speed filling while maintaining the sterility assurance levels required by international regulatory authorities. When evaluating a CDMO, confirm how many filling lines are RABS-equipped and the validation status of each.
What documentation should I request during CDMO due diligence for sterile fill-finish?
Key documentation to request includes: net committed capacity figures for your volume and format, validated line speed data for your specific container and fill volume, Restricted Access Barrier Systems (RABS) validation records, automated inspection performance data covering speed and detection technology, Aseptic Process Simulation (APS) records for the proposed filling line, technology transfer protocols and completed case studies for comparable products, the most recent Good Manufacturing Practice (GMP) inspection report summary and any outstanding observations, and the facility’s full certification portfolio across all target markets.
Which regulatory certifications should a CDMO hold for global pre-filled syringe supply?
For global supply, a CDMO should hold, at minimum, EU Good Manufacturing Practice (EU-GMP) certification for European market access and United States Food and Drug Administration (US FDA) certification for the US market. For supply to Japan, alignment with the Pharmaceuticals and Medical Devices Agency (PMDA) standards is required, typically through a local or Designated Marketing Authorisation Holder arrangement. A CDMO certified by multiple international health authorities demonstrates the documentation standards and operational discipline needed to support complex global supply programmes.
